DGIdb - CALCITRIOL Drug Record

CALCITRIOL chembl:CHEMBL846 ApprovedAntineoplastic

Alternate Names:

DIHYDROXYCHOLECALCIFEROL
DIHYDROXYVITAMIN D 3
TOPITRIOL
RO-21-5535
SILKIS
1ALPHA,25-DIHYDROXYCHOLECALCIFEROL
ROCALTROL
1ALPHA,25-DIHYDROXYVITAMIN D3
CALCIJEX
VECTICAL
RO-215535
CALCITRIOL
DECOSTRIOL
(1Α,3Β,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
1,25-DIHYDROXYCHOLECALCIFEROL
1A,25-(OH)2D3
1ALPHA,25(OH)2D3
1,25-DIHYDROXYVITAMIN D3
5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL
1Α,25(OH)2D3
25-DIHYDROXYCHOLECALCIFEROL
1A,25-DIHYDROXYCHOLECALCIFEROL
SOLTRIOL
1,25-DIHYDROXYVITAMIN D
1-ALPHA,25-DIHYDROXYVITAMIN D3
1,25-DHCC
(5Z,7E)-(1S,3R)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
RO 21-5535
1A,25-DIHYDROXYVITAMIN D3
(1S,3R,5Z,7E)-9,10-SECOCHOLESTA-5,7,10-TRIENE-1,3,25-TRIOL
(1R,3S,5Z)-5-{2-[(1R,3AS,4E,7AR)-1-[(2R)-6-HYDROXY-6-METHYLHEPTAN-2-YL]-7A-METHYL-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXANE-1,3-DIOL
DIHYDROXYVITAMIN D3
1Α,25-DIHYDROXYCHOLECALCIFEROL
TOPTRIOL
1,25 DIHYDROXYCHOLECALCIFEROL
(1ALPHA,3BETA,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-1,3,25-TRIOL
1-ALPHA-25-DIHYDROXYVITAMIN D3
CALCIJEX®
1Α,25-DIHYDROXYVITAMIN D3
ROCALTROL®
CALCITRIOLUM
(3B,5Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENETRIOL
chemidplus:32222-06-3
drugbank:00136
chembl:CHEMBL846
rxcui:1894
pubchem.compound:5280453

Drug Info:

Drug Indications	antineoplastic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antipsoriatic agent
Drug Class	antiosteoperosis agent
Year of Approval	1978
Drug Class	antihypocalcemic agents

(4 More Sources)

Publications:

Ames SK et al., 1999, Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children., J Bone Miner Res
Yamamoto H et al., 1999, The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine., J Bone Miner Res
Haussler MR et al., 1977, Basic and clinical concepts related to vitamin D metabolism and action (first of two parts)., N Engl J Med
Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res
Senel E et al., 2011, Painful purple plaques on the thighs of an immunosuppressed patient., Clin Exp Dermatol
Elnenaei MO et al., 2011, Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation., Br J Nutr
Ryan C et al., 2010, Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis., Br J Dermatol
Lambrinoudaki I et al., 2011, BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy., Eur J Neurol
Arabi A et al., 2009, Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls., Bone
Jehan F et al., 2008, Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment., J Clin Endocrinol Metab
Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
Dayangac-Erden D et al., 2007, Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients., Arch Dermatol Res
van Etten E et al., 2007, The vitamin D receptor gene FokI polymorphism: functional impact on the immune system., Eur J Immunol
d'Alésio A et al., 2005, Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls., Hum Mol Genet
Abrams SA et al., 2005, Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty., J Bone Miner Res
Halsall JA et al., 2005, Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis., Pharmacogenet Genomics
Morrison NA et al., 2005, Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis., Pharmacogenet Genomics
Palomba S et al., 2005, BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial., Osteoporos Int
Roth DE et al., 2004, Association between vitamin D receptor gene polymorphisms and response to treatment of pulmonary tuberculosis., J Infect Dis
International HapMap Consortium., 2003, The International HapMap Project., Nature
Arai H et al., 2001, The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene., J Bone Miner Res
Jurutka PW et al., 2000, The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB., Mol Endocrinol
Glorieux et al., 2001, The anti-proliferative effect of calcitriol on HL-60 cells is neutralized by uraemic biological fluids., Nephrol. Dial. Transplant.
Belorusova AY et al., 2014, Structural insights into the molecular mechanism of vitamin D receptor activation by lithocholic acid involving a new mode of ligand recognition., J Med Chem
Laverny G et al., 2009, Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3., J Med Chem
Wongmayura A et al., 2012, Novel vitamin D receptor ligands bearing a spherical hydrophobic core structure--comparison of bicyclic hydrocarbon derivatives with boron cluster derivatives., Bioorg Med Chem Lett
Lamblin M et al., 2010, An o-aminoanilide analogue of 1α,25-dihydroxyvitamin D(3) functions as a strong vitamin D receptor antagonist., J Med Chem
Lamblin M et al., 2010, Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids., Bioorg Med Chem
Reinhart, 2004, Vitamin D analogs: novel therapeutic agents for cardiovascular disease?, Curr Opin Investig Drugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Dossing et al., 2005, Receptor activator of NF-kappaB ligand protein expression in UMR-106 cells is differentially regulated by parathyroid hormone and calcitriol., J. Cell. Biochem.
Gyetko et al., 1988, Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester., J. Immunol.
Nazarova et al., 2004, Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth., Int. J. Cancer
Dackiw et al., 2004, Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer., Endocrinology
Ferla S et al., 2014, Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation., J Med Chem
Kruse et al., 1998, Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets., Eur. J. Pediatr.
Haq, 1986, 1,25-Dihydroxyvitamin D3 (calcitriol) suppresses IL-2 induced murine thymocyte proliferation., Thymus
Saunders et al., 1993, Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone., Anticancer Drugs
Beer et al., 2004, Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy., Cancer Epidemiol. Biomarkers Prev.

CALCITRIOL PHEX

Interaction Score: 11.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9835432

Sources:
NCI
CALCITRIOL CYP24A1

Interaction Score: 2.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25148392

Sources:
DTC
CALCITRIOL BTF3P11

Interaction Score: 2.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15849738

Sources:
NCI
CALCITRIOL GDF15

Interaction Score: 2.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15386353

Sources:
NCI
CALCITRIOL TG

Interaction Score: 0.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15319350

Sources:
NCI
CALCITRIOL VDR

Interaction Score: 0.45

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name DN-101,Asentar

Novel drug target Established target

Trial Name calcitriol, vitamin D3 derivative,Silkis, Vectical

PMIDs:
10320522 9933478 333287 21651652 21418277 20727239 20716226 20500803 19647104 18827005 18470879 17763859 17274004 16210379 15883634 15864137 15861036 15739035 15295697 14685227 11450701 10707958 11158396 24818857 19309155 22285943 20883026 20452225 15503649 11752352

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD
CALCITRIOL PLAU

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3139763

Sources:
NCI
CALCITRIOL MYC

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8490200 15598784

Sources:
NCI
CALCITRIOL IL2

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3492067

Sources:
NCI
CALCITRIOL GMNN

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CALCITRIOL AR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: CALCITRIOL
- Version: 01-August-2011
Alternate Names:

CALCITRIOL Primary Drug Name

Drug Info:

Drug Class antihypocalcemic agents

Year of Approval 1978

Drug Class antiosteoperosis agent

Publications:
TdgClinicalTrial: CALCITRIOL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antipsoriatic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: CALCITRIOL

Version: 02-September-2020

Alternate Names:

CHEMBL846 ChEMBL Drug ID

Drug Info:

Publications:

Ferla S et al., 2014, Small-molecule inhibitors of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1): synthesis and biological evaluation., J Med Chem

Wongmayura A et al., 2012, Novel vitamin D receptor ligands bearing a spherical hydrophobic core structure--comparison of bicyclic hydrocarbon derivatives with boron cluster derivatives., Bioorg Med Chem Lett

Laverny G et al., 2009, Synthesis and anti-inflammatory properties of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-24-oxo-vitamin D3, a hypocalcemic, stable metabolite of 1alpha,25-dihydroxy-16-ene-20-cyclopropyl-vitamin D3., J Med Chem

NCI: CALCITRIOL

Version: 14-September-2017

Alternate Names:

C330 NCI drug code

Drug Info:

Publications:

Nazarova et al., 2004, Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth., Int. J. Cancer

Kruse et al., 1998, Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets., Eur. J. Pediatr.

Dackiw et al., 2004, Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer., Endocrinology

PharmGKB: calcitriol

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Abrams SA et al., 2005, Vitamin D receptor Fok1 polymorphisms affect calcium absorption, kinetics, and bone mineralization rates during puberty., J Bone Miner Res

Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer

van Etten E et al., 2007, The vitamin D receptor gene FokI polymorphism: functional impact on the immune system., Eur J Immunol

TTD: Calcitriol
- Version: 2020.06.01
Alternate Names:

D0T2PL TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL846
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL846
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	DN-101,Asentar
Novel drug target	Established target
Trial Name	calcitriol, vitamin D3 derivative,Silkis, Vectical

agonist (activating)
antagonist (inhibitory)

CALCITRIOL Drug Record

CALCITRIOL chembl:CHEMBL846 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9835432

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25148392

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15849738

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15386353

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15319350

Sources: NCI

Interaction Types & Directionality: agonist (activating) antagonist (inhibitory)

Interaction Info: Trial Name DN-101,Asentar Novel drug target Established target Trial Name calcitriol, vitamin D3 derivative,Silkis, Vectical

PMIDs: 10320522 9933478 333287 21651652 21418277 20727239 20716226 20500803 19647104 18827005 18470879 17763859 17274004 16210379 15883634 15864137 15861036 15739035 15295697 14685227 11450701 10707958 11158396 24818857 19309155 22285943 20883026 20452225 15503649 11752352

Sources: DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3139763

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8490200 15598784

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3492067

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: CALCITRIOL

Alternate Names: CALCITRIOL Primary Drug Name

Drug Info: Drug Class antihypocalcemic agents Year of Approval 1978 Drug Class antiosteoperosis agent

Publications:

TdgClinicalTrial: CALCITRIOL

Alternate Names:

Drug Info: Drug Indications antipsoriatic agent Drug Class Small Molecule FDA Approval approved

Publications:

DTC: CALCITRIOL

Alternate Names: CHEMBL846 ChEMBL Drug ID

Drug Info:

NCI: CALCITRIOL

Alternate Names: C330 NCI drug code

Drug Info:

PharmGKB: calcitriol

Alternate Names:

Drug Info:

TTD: Calcitriol

Alternate Names: D0T2PL TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL846

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL846

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
9835432

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25148392

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
15849738

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15386353

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15319350

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

antagonist (inhibitory)

Interaction Info:

Trial Name DN-101,Asentar

Novel drug target Established target

Trial Name calcitriol, vitamin D3 derivative,Silkis, Vectical

PMIDs:
10320522 9933478 333287 21651652 21418277 20727239 20716226 20500803 19647104 18827005 18470879 17763859 17274004 16210379 15883634 15864137 15861036 15739035 15295697 14685227 11450701 10707958 11158396 24818857 19309155 22285943 20883026 20452225 15503649 11752352

Sources:
DTC TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

Interaction Types & Directionality:

n/a

PMIDs:
3139763

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8490200 15598784

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3492067

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CALCITRIOL Primary Drug Name

Drug Info:

Drug Class antihypocalcemic agents

Year of Approval 1978

Drug Class antiosteoperosis agent

Drug Info:

Drug Indications antipsoriatic agent

Drug Class Small Molecule

FDA Approval approved

Alternate Names:

CHEMBL846 ChEMBL Drug ID

Alternate Names:

C330 NCI drug code

Alternate Names:

D0T2PL TTD Drug ID